Gami­da Cell wins FDA ap­proval for new cord blood-based ther­a­py for can­cer pa­tients

The FDA on Mon­day ap­proved Is­rael-based Gami­da Cell’s Omisirge (omidu­bi­cel-on­lv), an al­lo­gene­ic cord blood-based cell ther­a­py used to quick­en the re­cov­ery of white blood cells …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER